The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Semaglutide

Ozempic · Wegovy · Rybelsus · Sema

A
Strong human RCT
FDA-approvedGLP-1 Receptor AgonistPeptideIncretin Mimetic
RouteInjectableFDA-approved
A
Evidence grade: Strong human RCT

Multiple high-quality randomized controlled trials in humans. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Ozempic / Wegovy / Rybelsus — GLP-1 Receptor Agonist — FDA-Approved — GLP-1 Receptor Agonist, Peptide, Incretin Mimetic.
Why people use it
Used primarily for weight loss.
What the evidence supports
Semaglutide is the most evidence-supported cardiometabolic intervention in this reference set, an FDA-approved drug and the compound most likely to produce clinically meaningful outcomes in the largest fraction of users.
If you only read one thing

Semaglutide has produced the most compelling human clinical evidence in obesity pharmacotherapy history. The STEP 1 -14.9% weight loss, SELECT's 20% MACE reduction, 4-year sustained weight loss data — these are not marginal effects. They represent a genuine paradigm shift in what pharmacological intervention can achieve in metabolic disease. The question nobody in the pharmaceutical industry wants to answer clearly: what happens when you stop? The STEP 4 withdrawal data showed two-thirds of lost weight returns within one year of discontinuation. The drug appears to be treating obesity the way antihypertensives treat hypertension — effectively while you take it, with return of the underlying condition when you stop. This has profound implications for how semaglutide should be conceptualized: not as a weight loss course, but as a chronic disease medication requiring potentially indefinite treatment. The commercial, behavioral, and public health implications of this framing are enormous. The chapter addresses both the extraordinary evidence and the discontinuation question honestly.

Check interactions →
Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
10human RCTs1human study1animal0in vitro

Represents the major STEP/SUSTAIN/PIONEER/SELECT randomized programs rather than every semaglutide trial; both subcutaneous and oral approved formulations have controlled human evidence.

Evidence reality check
Human evidence
11 human studies
10 randomized; 1 observational.
Preclinical base
1 lab signal
1 animal; 0 in-vitro/mechanistic.
Evidence snapshot
Semaglutide is the most evidence-supported cardiometabolic intervention in this reference set, an FDA-approved drug and the compound most likely to produce clinically meaningful outcomes in the largest fraction of users.
From the chapter quick-reference block.

Semaglutide is the most evidence-supported cardiometabolic intervention in this reference set, an FDA-approved drug and the compound most likely to produce clinically meaningful outcomes in the largest fraction of users. It is also not a cure for obesity.

The central tension resolved: semaglutide delivers weight loss (-14.9% at 68 weeks), cardiovascular protection (20% MACE reduction in SELECT), glycemic improvement, blood pressure reduction, and emerging organ protection (kidney, liver) with the largest and most rigorous evidence base among compounds in this reference set. It is a genuine pharmaceutical breakthrough. And when you stop taking it, most of the weight returns — because you have removed the pharmacological suppression of a chronic disease that was never cured. This is not a failure of the drug; it is the nature of the disease. The clinical and personal decision about whether to use semaglutide short-term, long-term, or indefinitely should be made with this pharmacological reality clearly understood.

Categories
Weight Loss & Metabolic
Properties
✓ FDA-approved✓ Human RCT
Evidence
AStrong human RCT
FDA-approved GLP-1 drug, not gray-market shorthand
Semaglutide is an FDA-approved drug — a regulated prescription GLP-1 receptor agonist. Ozempic (0.5-1.0mg weekly; T2D), Wegovy (0.25-2.4mg weekly; obesity and cardiovascular risk reduction), and Rybelsus (oral; T2D) are all the same molecule at different doses and formulations. Developed by Novo Nordisk. First approved by FDA in 2017 (Ozempic for T2D). Wegovy approved 2021 (obesity). Additional cardiovascular risk reduction indication approved March 2024 (SELECT trial basis).
The Evidence Standard
Semaglutide has the largest and most rigorous clinical trial program among compounds in this reference set. STEP 1-8 trials (obesity, T2D, various populations). SELECT cardiovascular outcomes trial (n=17,604; 4-year follow-up). SUSTAIN series (T2D, cardiovascular outcomes). Multiple systematic reviews, meta-analyses, and real-world cohort studies. Grade A evidence for weight loss, glycemic control, and cardiovascular outcomes. This is not extrapolated animal data or a single Phase 2b trial — this is a pharmaceutical with the gold standard of human evidence.
The STEP Trial Weight Loss
STEP 1 (NEJM 2021): n=1,961 adults with obesity; 68 weeks; Wegovy 2.4mg once weekly; mean weight loss -14.9% vs -2.4% placebo; net -12.5%. 50.5% of semaglutide participants achieved ≥15% weight loss; 32.0% achieved ≥20%. STEP 3 (with lifestyle intervention): -16.0%. STEP 2 (T2D): -9.6%. STEP trials represent the largest obesity pharmacotherapy RCT dataset published to date.
SELECT — The Cardiovascular Landmark
SELECT (NEJM 2023; 4-year data Nature Medicine 2024): n=17,604 adults with obesity/overweight + established CVD, no diabetes; mean 39.8 months follow-up; HR 0.80 (95% CI 0.72-0.90) for MACE — 20% reduction in cardiovascular death, nonfatal MI, nonfatal stroke. Cardiovascular benefit was independent of the degree of weight loss achieved. In 2024, FDA approved semaglutide (Wegovy 2.4mg) for the additional indication of reducing cardiovascular risk in adults with overweight/obesity and established CVD. Weight loss was sustained at 4 years: -10.2% semaglutide vs -1.5% placebo.
The Weight Rebound Question
STEP 4 withdrawal study: after 20 weeks of semaglutide then switched to placebo, participants regained 2/3 of lost weight within 1 year (NEJM 2022). Meta-analysis (Cureus 2025): semaglutide showed highest weight regain after discontinuation vs other GLP-1s: -5.15 kg mean regain. eClinicalMedicine systematic review (Nov 2025): confirmed rebound + +7.09 mmHg systolic BP rebound. HOWEVER, real-world Epic data (n=20,274; Jan 2024): 17.7% regained ALL weight, but 55.7% maintained weight or continued losing at 1 year. The rebound is real but the real-world picture is more nuanced than the clinical trial data suggests.
Compounded Semaglutide — 2025-2026 Status
Semaglutide was placed on the FDA drug shortage list due to demand exceeding supply. During shortage status, compounding pharmacies (503A and 503B) could legally compound semaglutide. The FDA removed semaglutide from the shortage list in early 2025. This triggered the requirement for compounding pharmacies to cease semaglutide compounding. Legal challenges from 503B pharmacies created a contested regulatory environment through 2025-2026. Independent assays of compounded semaglutide found potencies ranging from 68-122% of labeled strength — a significant quality variance. Community research chemical semaglutide is unregulated with no quality assurance.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
AOD-9604
C
Same class · Peptide

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

Cagrilintide
C
Same class · Peptide

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

Eloralintide
C
Same class · Peptide

Eli Lilly's Selective Amylin Receptor Agonist. The Most Recent Lancet Publication in this reference (December 2025). Phase 2 Completed August 2025: 9.5-20.1% Weight Loss vs 0.4% Placebo at 48 Weeks. Phase 3 Just Started Enrollment (December 2025). The AMY1R-Selective Design: 12x More Selective for AMY1R vs CTR — Potentially Addressing the Two Biggest Limitations of Non-Selective Amylin Agonists (Nausea and Medullary Thyroid Carcinoma Risk). Lilly's Amylin Answer to Tirzepatide's GIP Addition.

Check interactions